Hepatitis B vaccination and the rate of seroconversion in high risk contacts.
Twenty-seven employees of a blood transfusion centre, Calcutta were vaccinated with hepatitis B vaccine (recombinant DNA technology), 20 micrograms/1 ml intramuscularly on 0, 8, 32 weeks interval. The seroconversion rate at 8, 32, 40 weeks were 29.6%, 55.5% and 100% respectively. The recombinant hepatitis B vaccine is acceptable and safe. The seroconversion rate is comparable to plasma derived hepatitis B vaccine.
Sengupta
B
B
B R Singh Hospital, Calcutta.
Sarkar
A
A
De
M
M
Lahiri
P
P
Bhattacharya
D K
DK
D001771:Blood Banks; D001782:Blood Donors; D005260:Female; D006282:Health Personnel; D006509:Hepatitis B / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008403:Mass Screening; D009784:Occupational Diseases / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D012307:Risk Factors; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage*
D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; C075655:Recombivax HB; D014614:Vaccines, Synthetic